For example, Patisiran®, a siRNA targeting the Transthyretin protein causative for familial amyloid polyneuropathies or cardiomyopathies, was approved by the FDA and EMA, and this synthetic antisense oligonucleotide therapy product capturing the mRNA transcript of the Transthyretin gene is nowadays considered the standard therapy approach for these disorders. This evidence concerns the gene TTR and cardiomyopathy.